Cargando…

Upcoming immunotherapeutic combinations for B-cell lymphoma

After initial introduction for B-cell lymphomas as adjuvant therapies to established cancer treatments, immune checkpoint inhibitors and other immunotherapies are now integrated in mainstream regimens, both in adult and pediatric patients. We here provide an overview of the current status of combina...

Descripción completa

Detalles Bibliográficos
Autores principales: Greve, Patrick, Meyer-Wentrup, Friederike A G, Peperzak, Victor, Boes, Marianne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326875/
https://www.ncbi.nlm.nih.gov/pubmed/35919738
http://dx.doi.org/10.1093/immadv/ltab001
_version_ 1784757387108810752
author Greve, Patrick
Meyer-Wentrup, Friederike A G
Peperzak, Victor
Boes, Marianne
author_facet Greve, Patrick
Meyer-Wentrup, Friederike A G
Peperzak, Victor
Boes, Marianne
author_sort Greve, Patrick
collection PubMed
description After initial introduction for B-cell lymphomas as adjuvant therapies to established cancer treatments, immune checkpoint inhibitors and other immunotherapies are now integrated in mainstream regimens, both in adult and pediatric patients. We here provide an overview of the current status of combination therapies for B-cell lymphoma, by in-depth analysis of combination therapy trials registered between 2015–2020. Our analysis provides new insight into the rapid evolution in lymphoma treatment, as propelled by new additions to the treatment arsenal. We conclude with prospects on upcoming clinical trials which will likely use systematic testing approaches of more combinations of established chemotherapy regimens with new agents, as well as new combinations of immunotherapy and targeted therapy. Future trials will be set up as basket or umbrella-type trials to facilitate the evaluation of new drugs targeting specific genetic changes in the tumor or associated immune microenvironment. As such, lymphoma patients will benefit by receiving more tailored treatment that is based on synergistic effects of chemotherapy combined with new agents targeting specific aspects of tumor biology and the immune system.
format Online
Article
Text
id pubmed-9326875
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-93268752022-08-01 Upcoming immunotherapeutic combinations for B-cell lymphoma Greve, Patrick Meyer-Wentrup, Friederike A G Peperzak, Victor Boes, Marianne Immunother Adv TrialsWatch After initial introduction for B-cell lymphomas as adjuvant therapies to established cancer treatments, immune checkpoint inhibitors and other immunotherapies are now integrated in mainstream regimens, both in adult and pediatric patients. We here provide an overview of the current status of combination therapies for B-cell lymphoma, by in-depth analysis of combination therapy trials registered between 2015–2020. Our analysis provides new insight into the rapid evolution in lymphoma treatment, as propelled by new additions to the treatment arsenal. We conclude with prospects on upcoming clinical trials which will likely use systematic testing approaches of more combinations of established chemotherapy regimens with new agents, as well as new combinations of immunotherapy and targeted therapy. Future trials will be set up as basket or umbrella-type trials to facilitate the evaluation of new drugs targeting specific genetic changes in the tumor or associated immune microenvironment. As such, lymphoma patients will benefit by receiving more tailored treatment that is based on synergistic effects of chemotherapy combined with new agents targeting specific aspects of tumor biology and the immune system. Oxford University Press 2021-02-09 /pmc/articles/PMC9326875/ /pubmed/35919738 http://dx.doi.org/10.1093/immadv/ltab001 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Immunology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle TrialsWatch
Greve, Patrick
Meyer-Wentrup, Friederike A G
Peperzak, Victor
Boes, Marianne
Upcoming immunotherapeutic combinations for B-cell lymphoma
title Upcoming immunotherapeutic combinations for B-cell lymphoma
title_full Upcoming immunotherapeutic combinations for B-cell lymphoma
title_fullStr Upcoming immunotherapeutic combinations for B-cell lymphoma
title_full_unstemmed Upcoming immunotherapeutic combinations for B-cell lymphoma
title_short Upcoming immunotherapeutic combinations for B-cell lymphoma
title_sort upcoming immunotherapeutic combinations for b-cell lymphoma
topic TrialsWatch
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326875/
https://www.ncbi.nlm.nih.gov/pubmed/35919738
http://dx.doi.org/10.1093/immadv/ltab001
work_keys_str_mv AT grevepatrick upcomingimmunotherapeuticcombinationsforbcelllymphoma
AT meyerwentrupfriederikeag upcomingimmunotherapeuticcombinationsforbcelllymphoma
AT peperzakvictor upcomingimmunotherapeuticcombinationsforbcelllymphoma
AT boesmarianne upcomingimmunotherapeuticcombinationsforbcelllymphoma